Streetbeat News

MLTX

MoonLake Immunotherapeutics

https://www.moonlaketx.com

Industry

Biotechnology

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Open

51.98

Mkt cap

3.1B

Volume

401K

High

51.98

P/E Ratio

-38.45

52-wk high

64.98

Low

48.30

Div yield

N/A

52-wk low

37.55

Wedbush analyst Andreas Argyrides has reiterated an Outperform rating on MoonLake (NASDAQ:MLTX) and maintained a price target of $86.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 3:25 pm

US stocks traded higher with the Nasdaq Composite gaining around 50 points. Consumer discretionary shares jumped by 0.6% while real estate shares fell by 1.1%. DISH Network Corp reported Q3 revenue of $3.70 billion, missing the consensus of $3.72 billion. Carbon Revolution Public Limited shares shot up 546% after a merger with Twin Ridge Capital Acquisition Corp. Bluegreen Vacations Holding Corporation shares boosted by 106% after the company announced it would be acquired by Hilton Grand Vacations. Verb Technology Company shares were up by 52% amid the company announcing new technology integrations for its MARKET.live platform. MoonLake Immunotherapeutics shares dropped 25% after the company announced results of its phase 2 study treating active Psoriatic Arthritis. DISH Network Corporation shares were down 19% after the company reported Q3 results. EchoStar Corporation was down, falling 18% after the company reported worse-than-expected Q3 sales.

Portfolio Pulse from Lisa Levin

November 06, 2023 | 2:48 pm

MoonLake Immunotherapeutics announced the results of its phase 2 study for treating active Psoriatic Arthritis, causing its shares to trade lower.

Portfolio Pulse from Luke J Jacobi

November 06, 2023 | 1:22 pm

During Monday's pre-market session, several healthcare stocks experienced significant movement. Gainers included Celldex Therapeutics (CLDX), Sensei Biotherapeutics (SNSE), Baudax Bio (BXRX), CervoMed (CRVO), Repare Therapeutics (RPTX), and OptimizeRx (OPRX). Losers included Cerus (CERS), MoonLake (MLTX), NexImmune (NEXI), Acurx Pharmaceuticals (ACXP), Altamira Therapeutics (CYTO), and Kazia Therapeutics (KZIA).

Portfolio Pulse from Benzinga Insights

November 06, 2023 | 1:06 pm

MoonLake Immunotherapeutics (NASDAQ:MLTX) announced positive top-line results from its global Phase 2 ARGO trial evaluating the efficacy and safety of the Nanobody® sonelokimab in patients with active psoriatic arthritis. The primary endpoint ACR50 was met with up to 47% of patients on sonelokimab achieving ACR50 as early as week 12. All key secondary endpoints were also met. The discontinuation rate was below 4% and safety results were consistent with previously reported studies.

Portfolio Pulse from Charles Gross

November 05, 2023 | 4:22 pm

Stifel analyst Alex Thompson has initiated coverage on MoonLake (NASDAQ:MLTX) with a Buy rating and a price target of $74.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 9:57 am

MoonLake Immunotherapeutics (NASDAQ:MLTX) announced positive 24-week topline results from its Phase 2 MIRA trial of sonelokimab for moderate-to-severe hidradenitis suppurativa (HS). The data showed further improvements in HiSCR75 response rates and other clinically relevant outcomes. Needham maintains a Buy rating for MLTX, with a price target of $76. MLTX shares are up 10.20% at $60.24.

Portfolio Pulse from Vandana Singh

October 16, 2023 | 6:30 pm

The article reports on the significant stock movements in Monday's mid-day session. Notable gainers include MingZhu Logistics Holdings Limited, PCTEL, Inc., and Almacenes Éxito S.A., while Streamline Health Solutions, Inc., Aldeyra Therapeutics, Inc., and Biocept, Inc. were among the biggest losers. The article also mentions several other companies whose stocks experienced significant changes.

Portfolio Pulse from Lisa Levin

October 16, 2023 | 5:09 pm

Several US stocks recorded significant gains on Monday, with PCTEL, Inc. (NASDAQ:PCTI) leading the pack with a 47.3% increase following its acquisition by Amphenol Corporation (NYSE:APH). Other notable gainers include Almacenes Éxito S.A. (NYSE:EXTO), E2open Parent Holdings, Inc. (NYSE:ETWO), Prothena Corporation plc (NASDAQ:PRTA), and Alignment Healthcare, Inc. (NASDAQ:ALHC), which saw its stock upgraded by Raymond James. Lululemon Athletica Inc. (NASDAQ:LULU) also climbed 9.8% after it was announced the stock will join the S&P 500.

Portfolio Pulse from Lisa Levin

October 16, 2023 | 4:08 pm

MoonLake (NASDAQ:MLTX) has received mostly bullish ratings from analysts in the last quarter, with an average price target of $75.8, a significant increase from the previous average of $51.00.

Portfolio Pulse from Benzinga Insights

October 16, 2023 | 4:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.